Report cover image

Global Infliximab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 193 Pages
SKU # APRC20278166

Description

Summary

According to APO Research, The global Infliximab Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Infliximab Injection include Yuxi Jiahe Biotechnology, Taizhou Maiboteike Pharmaceuticals, Hangzhou Bozhirui Biopharmaceuticals, Pfizer, Nippon Kayaku, Nichiiko, Janssen Biologics, Celltrion and Ayumi Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Infliximab Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Infliximab Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Infliximab Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Infliximab Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Infliximab Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Infliximab Injection sales, projected growth trends, production technology, application and end-user industry.

Infliximab Injection Segment by Company

Yuxi Jiahe Biotechnology
Taizhou Maiboteike Pharmaceuticals
Hangzhou Bozhirui Biopharmaceuticals
Pfizer
Nippon Kayaku
Nichiiko
Janssen Biologics
Celltrion
Ayumi Pharmaceuticals
AMGEN
Infliximab Injection Segment by Type

Original Drug
Generic Drug
Infliximab Injection Segment by Application

Hospital
Clinic
Other
Infliximab Injection Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infliximab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infliximab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infliximab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Infliximab Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Infliximab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Infliximab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Infliximab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Infliximab Injection Market Size, 2020 VS 2024 VS 2031
1.3 Global Infliximab Injection Market Size Estimates and Forecasts (2020-2031)
1.4 Global Infliximab Injection Sales Estimates and Forecasts (2020-2031)
1.5 Global Infliximab Injection Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Infliximab Injection Market Dynamics
2.1 Infliximab Injection Industry Trends
2.2 Infliximab Injection Industry Drivers
2.3 Infliximab Injection Industry Opportunities and Challenges
2.4 Infliximab Injection Industry Restraints
3 Infliximab Injection Market by Manufacturers
3.1 Global Infliximab Injection Revenue by Manufacturers (2020-2025)
3.2 Global Infliximab Injection Sales by Manufacturers (2020-2025)
3.3 Global Infliximab Injection Average Sales Price by Manufacturers (2020-2025)
3.4 Global Infliximab Injection Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Infliximab Injection Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Infliximab Injection Manufacturers, Product Type & Application
3.7 Global Infliximab Injection Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Infliximab Injection Market CR5 and HHI
3.8.2 Global Top 5 and 10 Infliximab Injection Players Market Share by Revenue in 2024
3.8.3 2024 Infliximab Injection Tier 1, Tier 2, and Tier 3
4 Infliximab Injection Market by Type
4.1 Infliximab Injection Type Introduction
4.1.1 Original Drug
4.1.2 Generic Drug
4.2 Global Infliximab Injection Sales by Type
4.2.1 Global Infliximab Injection Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Infliximab Injection Sales by Type (2020-2031)
4.2.3 Global Infliximab Injection Sales Market Share by Type (2020-2031)
4.3 Global Infliximab Injection Revenue by Type
4.3.1 Global Infliximab Injection Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Infliximab Injection Revenue by Type (2020-2031)
4.3.3 Global Infliximab Injection Revenue Market Share by Type (2020-2031)
5 Infliximab Injection Market by Application
5.1 Infliximab Injection Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Other
5.2 Global Infliximab Injection Sales by Application
5.2.1 Global Infliximab Injection Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Infliximab Injection Sales by Application (2020-2031)
5.2.3 Global Infliximab Injection Sales Market Share by Application (2020-2031)
5.3 Global Infliximab Injection Revenue by Application
5.3.1 Global Infliximab Injection Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Infliximab Injection Revenue by Application (2020-2031)
5.3.3 Global Infliximab Injection Revenue Market Share by Application (2020-2031)
6 Global Infliximab Injection Sales by Region
6.1 Global Infliximab Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Infliximab Injection Sales by Region (2020-2031)
6.2.1 Global Infliximab Injection Sales by Region (2020-2025)
6.2.2 Global Infliximab Injection Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Infliximab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Infliximab Injection Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Infliximab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Infliximab Injection Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Infliximab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Infliximab Injection Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Infliximab Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Infliximab Injection Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Infliximab Injection Revenue by Region
7.1 Global Infliximab Injection Revenue by Region
7.1.1 Global Infliximab Injection Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Infliximab Injection Revenue by Region (2020-2025)
7.1.3 Global Infliximab Injection Revenue by Region (2026-2031)
7.1.4 Global Infliximab Injection Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Infliximab Injection Revenue (2020-2031)
7.2.2 North America Infliximab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Infliximab Injection Revenue (2020-2031)
7.3.2 Europe Infliximab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Infliximab Injection Revenue (2020-2031)
7.4.2 Asia-Pacific Infliximab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Infliximab Injection Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Infliximab Injection Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Yuxi Jiahe Biotechnology
8.1.1 Yuxi Jiahe Biotechnology Comapny Information
8.1.2 Yuxi Jiahe Biotechnology Business Overview
8.1.3 Yuxi Jiahe Biotechnology Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Yuxi Jiahe Biotechnology Infliximab Injection Product Portfolio
8.1.5 Yuxi Jiahe Biotechnology Recent Developments
8.2 Taizhou Maiboteike Pharmaceuticals
8.2.1 Taizhou Maiboteike Pharmaceuticals Comapny Information
8.2.2 Taizhou Maiboteike Pharmaceuticals Business Overview
8.2.3 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Portfolio
8.2.5 Taizhou Maiboteike Pharmaceuticals Recent Developments
8.3 Hangzhou Bozhirui Biopharmaceuticals
8.3.1 Hangzhou Bozhirui Biopharmaceuticals Comapny Information
8.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
8.3.3 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Portfolio
8.3.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Pfizer Infliximab Injection Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Nippon Kayaku
8.5.1 Nippon Kayaku Comapny Information
8.5.2 Nippon Kayaku Business Overview
8.5.3 Nippon Kayaku Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Nippon Kayaku Infliximab Injection Product Portfolio
8.5.5 Nippon Kayaku Recent Developments
8.6 Nichiiko
8.6.1 Nichiiko Comapny Information
8.6.2 Nichiiko Business Overview
8.6.3 Nichiiko Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Nichiiko Infliximab Injection Product Portfolio
8.6.5 Nichiiko Recent Developments
8.7 Janssen Biologics
8.7.1 Janssen Biologics Comapny Information
8.7.2 Janssen Biologics Business Overview
8.7.3 Janssen Biologics Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Janssen Biologics Infliximab Injection Product Portfolio
8.7.5 Janssen Biologics Recent Developments
8.8 Celltrion
8.8.1 Celltrion Comapny Information
8.8.2 Celltrion Business Overview
8.8.3 Celltrion Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Celltrion Infliximab Injection Product Portfolio
8.8.5 Celltrion Recent Developments
8.9 Ayumi Pharmaceuticals
8.9.1 Ayumi Pharmaceuticals Comapny Information
8.9.2 Ayumi Pharmaceuticals Business Overview
8.9.3 Ayumi Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Ayumi Pharmaceuticals Infliximab Injection Product Portfolio
8.9.5 Ayumi Pharmaceuticals Recent Developments
8.10 AMGEN
8.10.1 AMGEN Comapny Information
8.10.2 AMGEN Business Overview
8.10.3 AMGEN Infliximab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 AMGEN Infliximab Injection Product Portfolio
8.10.5 AMGEN Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Infliximab Injection Value Chain Analysis
9.1.1 Infliximab Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Infliximab Injection Production Mode & Process
9.2 Infliximab Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Infliximab Injection Distributors
9.2.3 Infliximab Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.